- ASSISTANT CLINICAL PROFESSOR Psychiatry, Mood and Personality Disorders
- Clinical Interests:
Generalized Anxiety Disorder
Co-investigator, NIMH 1R01-MH071827
The aim of this project is to understand the amygdala and prefrontal cortex in panic disorder patients as compared to a normal population in both states of anticipatory anxiety and panic through PET imaging.
Principal Investigator, NARSAD Young Investigators Award
The aim of this project is to understand the amygdala and prefrontal cortex in panic disorder patients in both states of anticipatory anxiety and panic after successful treatment with cognitive behavior therapy through PET imaging.
Aaronson CJ, Shear MK, Goetz RR, Allen LB, Barlow DH, White KS, Ray S, Money R, Saksa JR, Woods SW, Gorman JM. Predictors and time course of response among panic disorder patients treated with CBT. Journal of Clinical Psychiatry 2008; 69: 418-424.
Aaronson CJ, Katzman GP, Gorman JM. Combination pharmacothery and psychotherapy for the treatment of major depression and anxiety disorders. In: Nathan PE, Gorman JM, editors. A guide to treatments that work, 3rd ed.
Garakani A, Buchsbaum MS, Newmark RE, Goodman C, Aaronson CJ, Martinez JM, Torosjan Y, Gorman JM. The effect of doxapram on brain imaging in patients with panic disorder. European Neuropsychopharmacology 2007; 17: 672-686.
Aaronson CJ, Bender DS, Skodol AE, Gunderson JG. Comparison of attachment styles in borderline personality disorder and obsessive-compulsive personality disorder. Psychiatric Quarterly 2006; 77(1): 69-80.
Garakani A, Aaronson CJ, Martinez JM, Buchsbaum MS, Gorman JM. The effect of cognitive behavioral therapy on brain imaging and neuroendocrine responses in patients with panic disorder. Neuropsychopharmacology 2004; 29(Suppl 1): S145.
Aaronson CJ. Separation Anxiety Disorder in Adults with Borderline Personality Disorder. (Doctoral dissertation, Columbia University, 2001) [abstract]. Dissertation Abstracts International. 2002; 62:.
Fyer AJ, Mannuzza S, Gallops M, Martin LY, Aaronson C, E. Familial Transmission of Simple Phobias and Fears. Archives of General Psychiatry 1990; 47: 252-256.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Aaronson did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
1160 Fifth Avenue Floor Basement
New York, NY 10029
297 Knollwood Road
White Plains, NY 10607
740 West End Ave
New York, NY 10025